Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/31754
Title: Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline.
Austin Authors: Ossenkoppele, Rik;Pichet Binette, Alexa;Groot, Colin;Smith, Ruben;Strandberg, Olof;Palmqvist, Sebastian;Stomrud, Erik;Tideman, Pontus;Ohlsson, Tomas;Jögi, Jonas;Johnson, Keith;Sperling, Reisa;Doré, Vincent ;Masters, Colin L ;Rowe, Christopher C ;Visser, Denise;van Berckel, Bart N M;van der Flier, Wiesje M;Baker, Suzanne;Jagust, William J;Wiste, Heather J;Petersen, Ronald C;Jack, Clifford R;Hansson, Oskar
Affiliation: Lund University, Clinical Memory Research Unit, Lund, Sweden.
Department of Radiation Physics, Skåne University Hospital, Lund, Sweden.
Skåne University Hospital, Department of Clinical Physiology and Nuclear Medicine, Lund, Sweden.
Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
The Australian e-Health Research Centre CSIRO Melbourne Victoria Australia, Melbourne, Victoria, Australia.
The Florey Institute of Neuroscience and Mental Health
Molecular Imaging and Therapy
Amsterdam Neuroscience, Neurodegeneration, Amsterdam, the Netherlands.
Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, the Netherlands.
Lawrence Berkeley National Laboratory, Berkeley, CA, USA.
Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
Department of Neurology, Mayo Clinic, Rochester, MN, USA.
Department of Radiology, Mayo Clinic, Rochester, MN, USA.
Issue Date: Nov-2022
Date: 2022
Publication information: Nature Medicine 2022
Abstract: A major unanswered question in the dementia field is whether cognitively unimpaired individuals who harbor both Alzheimer's disease neuropathological hallmarks (that is, amyloid-β plaques and tau neurofibrillary tangles) can preserve their cognition over time or are destined to decline. In this large multicenter amyloid and tau positron emission tomography (PET) study (n = 1,325), we examined the risk for future progression to mild cognitive impairment and the rate of cognitive decline over time among cognitively unimpaired individuals who were amyloid PET-positive (A+) and tau PET-positive (T+) in the medial temporal lobe (A+TMTL+) and/or in the temporal neocortex (A+TNEO-T+) and compared them with A+T- and A-T- groups. Cox proportional-hazards models showed a substantially increased risk for progression to mild cognitive impairment in the A+TNEO-T+ (hazard ratio (HR) = 19.2, 95% confidence interval (CI) = 10.9-33.7), A+TMTL+ (HR = 14.6, 95% CI = 8.1-26.4) and A+T- (HR = 2.4, 95% CI = 1.4-4.3) groups versus the A-T- (reference) group. Both A+TMTL+ (HR = 6.0, 95% CI = 3.4-10.6) and A+TNEO-T+ (HR = 7.9, 95% CI = 4.7-13.5) groups also showed faster clinical progression to mild cognitive impairment than the A+T- group. Linear mixed-effect models indicated that the A+TNEO-T+ (β = -0.056 ± 0.005, T = -11.55, P < 0.001), A+TMTL+ (β = -0.024 ± 0.005, T = -4.72, P < 0.001) and A+T- (β = -0.008 ± 0.002, T = -3.46, P < 0.001) groups showed significantly faster longitudinal global cognitive decline compared to the A-T- (reference) group (all P < 0.001). Both A+TNEO-T+ (P < 0.001) and A+TMTL+ (P = 0.002) groups also progressed faster than the A+T- group. In summary, evidence of advanced Alzheimer's disease pathological changes provided by a combination of abnormal amyloid and tau PET examinations is strongly associated with short-term (that is, 3-5 years) cognitive decline in cognitively unimpaired individuals and is therefore of high clinical relevance.
URI: https://ahro.austin.org.au/austinjspui/handle/1/31754
DOI: 10.1038/s41591-022-02049-x
ORCID: 0000-0003-1584-7477
0000-0001-5218-3337
0000-0001-7147-0112
0000-0002-9267-1930
0000-0002-8051-0558
0000-0002-5299-3628
0000-0001-8766-6224
0000-0002-4458-113X
0000-0002-8178-6601
0000-0001-7916-622X
0000-0001-8467-7286
Journal: Nature Medicine
Start page: 2381
End page: 2387
PubMed URL: 36357681
ISSN: 1546-170X
Type: Journal Article
Subjects: Amyloid
tau PET-positive cognitively unimpaired
Alzheimer Disease/pathology
tau Proteins/metabolism
Brain/metabolism
Cognitive Dysfunction/diagnostic imaging
Positron-Emission Tomography/methods
Amyloid/metabolism
Amyloid beta-Peptides/metabolism
Appears in Collections:Journal articles

Show full item record

Page view(s)

40
checked on Jul 19, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.